Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 8/20 | 0.46 |
| ▸ | CA2 | P00918 | 8/20 | 0.46 |
| ▸ | CA9 | Q16790 | 7/20 | 0.46 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.46 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA7 | P43166 | 3/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.46 |
| ▸ | CA3 | P07451 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | CA6 | P23280 | 2/20 | 0.46 |
| ▸ | CA5A | P35218 | 2/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3826183 | 1.00 | THRB (0.57) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL10581038 | 1.00 | THRB (0.57) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL22957 | 1.00 | THRB (0.57) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL2119344 | 1.00 | THRB (0.57) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL21218973 | 1.00 | THRB (0.57) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL1067348 | 1.00 | THRB (0.57) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL6827456 | 1.00 | THRB (0.57) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL10491770 | 1.00 | THRB (0.57) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL4162714 | 1.00 | THRB (0.57) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL8394850 | 1.00 | THRB (0.57) | THRBTSHRMEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8216609-B2 | Release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents; a process for preparing the dosage form. | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-07-10 | — | — | US | claimed |
| EP-1558220-B1 | ORAL COMPOSITIONS FOR TREATMENT OF DIABETES | WOCKHARDT LTD (IN) | 2010-02-10 | — | — | EP | claimed |
| US-20240041775-A1 | NEW MODIFIED RELEASE ORAL CONTRACEPTIVE COMPOSITION | CHEMO RESEARCH, S.L. (ES) | 2024-02-08 | — | — | US | disclosed |
| EP-4248938-A1 | FLEXIBLE AND SOLID MAKE-UP PRODUCT, AND A SWATCH OF MAKE-UP PRODUCTS | Chromavis S.p.A. (IT) | 2023-09-27 | — | — | EP | disclosed |
| US-20230285266-A1 | FLEXIBLE AND SOLID MAKE-UP PRODUCT, AND A SWATCH OF MAKE-UP PRODUCTS | CHROMAVIS SPA (IT) | 2023-09-14 | — | — | US | disclosed |
| EP-4196098-A1 | NEW MODIFIED RELEASE ORAL CONTRACEPTIVE COMPOSITION | Chemo Research, S.L. (ES) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022034209-A1 | NEW MODIFIED RELEASE ORAL CONTRACEPTIVE COMPOSITION | CHEMO RESEARCH, S.L. (ES) | 2022-02-17 | — | — | WO | disclosed |
| EP-3954364-A1 | NEW MODIFIED RELEASE ORAL CONTRACEPTIVE COMPOSITION | Chemo Research, S.L. (ES) | 2022-02-16 | — | — | EP | disclosed |
| WO-2020054590-A1 | WATER-IN-OIL EMULSION COSMETIC COMPOSITION | 株式会社 資生堂 | 2020-03-19 | — | — | WO | disclosed |
| EP-2352494-B1 | NOVEL AND POTENT TAPENTADOL DOSAGE FORMS | GRUENENTHAL GMBH (DE) | 2019-10-09 | — | — | EP | disclosed |
| US-20170216212-A1 | TAPENTADOL COMPOSITIONS | GRUENENTHAL GMBH (DE) | 2017-08-03 | — | — | US | disclosed |
| US-20080026054-A1 | Novel anelgesic combination | NECTID INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20070219107-A1 | Sheet-Like Body Cleaning Material | KAO CORPORATION (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20070172525-A1 | Anti-diabetic combinations | NECTID, INC. | 2007-07-26 | — | — | US | disclosed |
| EP-1558220-A4 | ORAL COMPOSITIONS FOR TREATMENT OF DISEASES | WOCKHARDT LTD (IN) | 2006-07-12 | — | — | EP | disclosed |
| US-20060134206-A1 | Oral compositions for treatment of diseases | WOCKHARDT LIMITED (IN) | 2006-06-22 | — | — | US | disclosed |
| US-7056952-B1 | for example, 3'-hydroxy-dihydrodaidzein, 5-hydroxy-O-demethylangolesin; for treating hormone dependent conditions and other diseases and disorders; anticarcinogenic agents | G.J. CONSULTANTS PTY. LTD. (AU) | 2006-06-06 | — | — | US | disclosed |
| EP-1558220-A1 | ORAL COMPOSITIONS FOR TREATMENT OF DISEASES | Wockhardt Limited (IN) | 2005-08-03 | — | — | EP | disclosed |
| WO-2005009412-A1 | ORAL COMPOSITIONS FOR TREATMENT OF DISEASES | WOCKHARDT LIMITED (IN) | 2005-02-03 | — | — | WO | disclosed |
| US-4405736-A | 2,2,6,6-Tetramethyl-4-piperidyl spiro aliphatic ethers and stabilizers for synthetic polymers | ADEKA ARGUS CHEMICAL CO., LTD. (JP) | 1983-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216212-A1 | TAPENTADOL COMPOSITIONS | GABRQ, GABRB3, GABRB2 | THRB 1182/4885TSHR 2160/4885MEN1 4736/4885 |
| US-20080026054-A1 | Novel anelgesic combination | OPRD1, OPRL1, NSD2 | THRB 3340/4885TSHR 3692/4885MEN1 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.